Immunotherapy venture raises $48 million

Image: T-cells

A visualization shows T-cells communicating via the immune synapse. (Credit: Alpine BioVentures)

Seattle’s Alpine Immune Sciences says it has closed a $48 million Series A financing round, to fund the development of next-generation therapies that tweak the body’s immune system to fight cancer and autoimmune diseases.

Immunotherapy ranks among the hottest topics in cancer research nowadays. The company’s executive chairman and acting CEO, Mitchell Gold, said in a statementthat the new infusion of investment “recognizes the tremendous potential” for the field and for Alpine Immune Sciences.

“AIS is taking a unique approach to modulating the immune system through the directed evolution of naturally occurring ligands – creating the next generation of cancer and autoimmune therapeutics with our vIgD platform,” Gold said.

The company is working on drugs that can activate the immune system to attack cancer cells, or keep the immune system from attacking healthy cells. The stand-down effect could ease such autoimmune disorders as Crohn’s disease, lupus and arthritis.

Get the full story on GeekWire.

About Alan Boyle

Award-winning science writer, creator of Cosmic Log, author of "The Case for Pluto: How a Little Planet Made a Big Difference," president of the Council for the Advancement of Science Writing. Check out "About Alan Boyle" for more fun facts.
This entry was posted in GeekWire and tagged , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.